Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
about
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsA periodic table for cancerThe PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.Operative management of metastatic melanoma in bone may require en bloc resection of diseaseTumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanomaThe Prognostic and Clinicopathological Significance of Tumor-Associated Macrophages in Patients with Gastric Cancer: A Meta-Analysis.Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid.Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysisEnhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines.The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.The immune escape in melanoma: role of the impaired dendritic cell function.The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.Immunotherapy of melanoma: present options and future promises.Safety of pembrolizumab for the treatment of melanoma.Combined effects of pericytes in the tumor microenvironment.The importance of the tumor microenvironment in the therapeutic management of cancer.Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.Emerging immunotherapy in pediatric lymphoma.Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.Immune and molecular correlates in melanoma treated with immune checkpoint blockade.Visualization of Tumor-Immune Interaction - Target-Specific Imaging of S100A8/A9 Reveals Pre-Metastatic Niche EstablishmentImmune Checkpoint Blockade in Hepatocellular Carcinoma.Blockade of PD-1 or p38 MAP kinase signaling enhances senescent human CD8(+) T-cell proliferation by distinct pathways.PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer.miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion.Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene.Immune system and melanoma biology: a balance between immunosurveillance and immune escape.Pembrolizumab for the treatment of melanoma.Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.EBV⁺ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8⁺ Intratumoral Lymphocytes.A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions.Immunotherapy efficacy and gender: discovery in precision medicine
P2860
Q26797478-44DE3D79-83C4-4E56-8ADB-B19E6D16C393Q26858878-C9DC7992-D55F-4EF6-8D0F-32BF6ADA0203Q33888982-4DE352EE-91C2-4FA9-9EC3-880A2A78F68FQ34161382-D4C02860-DE0E-463D-91FE-9C6CC2099A33Q36108254-738C7167-574D-481E-B6CD-931C7E17BDE7Q36247826-1C4F6FAF-15B5-4AF3-A159-D7508EC7EBC7Q36853857-118FF0F4-53D3-4EFE-B66C-A467D927D04DQ36891533-E17039F8-8CF9-4106-8296-FC64AC655CA4Q37142487-A003142A-23C6-434E-AD17-A4F8DD7CFF02Q37385372-F1F80E63-BCF9-4B1A-8CE8-465D923D8B1AQ37457628-B7030148-0FB1-4C23-B4D3-95252168586DQ38219369-3C42A6FF-3F38-49CF-AED4-ECE4A5741B54Q38250071-3B1862CB-B440-4A86-B639-A3232A290F43Q38285859-56D67051-5F05-4C49-B5AF-4971A0F28674Q38318683-F7DA84B0-E3E3-4B57-9AFD-5665C120D258Q38451331-7683D42E-1B8F-4D4D-949E-82DB4048BAF0Q38497294-09CB1F34-1F83-4849-BD11-0BEE1B9851F8Q38534294-B0D36658-5898-44AF-914E-68B99434EB82Q38600760-E332EF3F-E78A-4CDC-9594-09AE667BCA20Q38652326-13A4A829-F691-45EF-8155-3DA672AD6F35Q38753142-69A42CC4-7170-4DFA-9949-8502AB17541CQ38756832-9AF1A4B8-1558-4FF0-9302-79F7AE66AB0DQ38804604-3664E157-176C-42D4-A18C-F044A637A918Q38838649-DBD43118-321D-4586-88E3-EDB4F2CCDC53Q39329603-F6A0F321-59CC-4C17-81FB-557FC3948CE1Q41114263-07013758-B6F9-4B54-BD5A-66480E403605Q41355749-3303D68D-31F7-49DE-89E8-E3CF194351DFQ41468737-544B13F0-4984-4A7D-AEBC-8034F220D27FQ41709427-0C47F23A-FD79-4A88-9E30-3B2AD8C5012DQ41992370-F1E24003-371B-4A61-82FB-466A01C5022DQ42351579-458054C3-FF1A-4ACA-9FA5-825183240CBAQ47547580-22D25A56-FB66-472A-A3B0-5881120DC659Q49166036-BEBBA32B-8F47-46B4-A951-AB9BE4801809Q50957132-0F823004-6DED-492E-8DC7-47166032D975Q51416101-91C2A7D2-5514-4EAF-BEB4-112F150A11DCQ52893153-BD52247C-E38D-432C-B04E-8FF8D69745C8Q53249720-C9743DB4-BDE3-4B3C-AA95-325CA3A589CAQ55082025-315FF830-358A-4E2A-B6D0-0479D5CBA20BQ55336684-64E143EC-D66F-40AF-BB61-5E80095471C1Q58562489-1A10A007-5AD6-4DEE-8FC1-042D4EBF71DC
P2860
Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeting the PD1/PD-L1 axis i ...... challenges and opportunities.
@ast
Targeting the PD1/PD-L1 axis i ...... challenges and opportunities.
@en
Targeting the PD1/PD-L1 axis i ...... challenges and opportunities.
@nl
type
label
Targeting the PD1/PD-L1 axis i ...... challenges and opportunities.
@ast
Targeting the PD1/PD-L1 axis i ...... challenges and opportunities.
@en
Targeting the PD1/PD-L1 axis i ...... challenges and opportunities.
@nl
prefLabel
Targeting the PD1/PD-L1 axis i ...... challenges and opportunities.
@ast
Targeting the PD1/PD-L1 axis i ...... challenges and opportunities.
@en
Targeting the PD1/PD-L1 axis i ...... challenges and opportunities.
@nl
P2093
P1476
Targeting the PD1/PD-L1 axis i ...... challenges and opportunities.
@en
P2093
Barbara Merelli
Daniela Massi
Laura Cattaneo
Mario Mandalà
P304
P356
10.1016/J.CRITREVONC.2013.08.002
P577
2013-08-28T00:00:00Z